Maximum tumor diameter: a simple independent predictor for biochemical recurrence after radical prostatectomy

被引:20
作者
Fukuhara, H. [1 ]
Kume, H. [1 ]
Suzuki, M. [1 ]
Fujimura, T. [1 ]
Enomoto, Y. [1 ]
Nishimatsu, H. [1 ]
Ishikawa, A. [1 ]
Homma, Y. [1 ]
机构
[1] Univ Tokyo, Dept Urol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan
关键词
prostatectomy; biochemical recurrence; tumor diameter; MULTIVARIATE-ANALYSIS; ANTIGEN RECURRENCE; PROGNOSTIC-FACTORS; CANCER; SPECIMENS; VOLUME; CARCINOMA; FAILURE; PROGRESSION; THERAPY;
D O I
10.1038/pcan.2010.17
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have suggested that maximum tumor diameter (MTD) is a predictor of PSA recurrence or biochemical recurrence (BCR) in prostate cancer after radical prostatectomy (RP). The significance of MTD in BCR prediction was evaluated using RP specimens of 364 patients with a BCR of 18% (n=66) during a mean follow-up of 37.4 months (range: 10-109 months). MTD was defined as the largest diameter of the largest tumor, and its median MTD was 15mm (range: 0.9-50 mm). MTD was significantly associated with pre-operative PSA levels, pathological T stage, Gleason's score and positive surgical margin. In a univariate analysis, pathological T stage, Gleason's score, positive surgical margin and MTD were associated significantly with the risk of BCR. Patients with >20mm MTD had a significantly higher risk of BCR than did those with <= 20mm MTD (P<0.001). Cox multivariate models indicated that pathological stage, Gleason's score, positive surgical margin and MTD were independent prognostic factors for BCR. MTD would be a useful tool for predicting BCR, as calculation of MTD is a simple and reliable measure. Prostate Cancer and Prostatic Diseases (2010) 13, 244-247; doi:10.1038/pcan.2010.17; published online 22 June 2010
引用
收藏
页码:244 / 247
页数:4
相关论文
共 24 条
  • [1] Carvalhal GF, 2000, CANCER, V89, P1308, DOI 10.1002/1097-0142(20000915)89:6<1308::AID-CNCR16>3.0.CO
  • [2] 2-3
  • [3] Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer
    Dvorak, T
    Chen, MH
    Renshaw, AA
    Loffredo, M
    Richie, JP
    D'Amico, AV
    [J]. UROLOGY, 2005, 66 (05) : 1024 - 1028
  • [4] Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer
    Eichelberger, LE
    Koch, MO
    Eble, JN
    Ulbright, TM
    Juliar, BE
    Cheng, L
    [J]. MODERN PATHOLOGY, 2005, 18 (07) : 886 - 890
  • [5] Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer
    Eichelberger, LE
    Koch, MO
    Daggy, JK
    Ulbright, TM
    Eble, JN
    Cheng, L
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (03) : 386 - 391
  • [6] IS TUMOR VOLUME AN INDEPENDENT PREDICTOR OF PROGRESSION FOLLOWING RADICAL PROSTATECTOMY - A MULTIVARIATE-ANALYSIS OF 185 CLINICAL STAGE-B ADENOCARCINOMAS OF THE PROSTATE WITH 5 YEARS OF FOLLOW-UP
    EPSTEIN, JI
    CARMICHAEL, M
    PARTIN, AW
    WALSH, PC
    [J]. JOURNAL OF UROLOGY, 1993, 149 (06) : 1478 - 1481
  • [7] Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy - The 15-year Johns Hopkins experience
    Han, M
    Partin, AW
    Pound, CR
    Epstein, JI
    Walsh, PC
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2001, 28 (03) : 555 - +
  • [8] Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy
    Hernandez, David J.
    Nielsen, Matthew E.
    Han, Misop
    Trock, Bruce J.
    Partin, Alan W.
    Walsh, Patrick C.
    Epstein, Jonathan I.
    [J]. UROLOGY, 2008, 72 (01) : 172 - 176
  • [9] Is tumor volume an independent prognostic factor in clinically localized prostate cancer?
    Kikuchi, E
    Scardino, PT
    Wheeler, TM
    Slawin, KM
    Ohori, M
    [J]. JOURNAL OF UROLOGY, 2004, 172 (02) : 508 - 511
  • [10] Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer
    Kupelian, P
    Katcher, J
    Levin, H
    Zippe, C
    Klein, E
    [J]. UROLOGY, 1996, 48 (02) : 249 - 260